Principle
Immunotherapy is presented in the context of tumour entity, treatment setting and available clinical evidence.
Patient selection
Eligibility can depend on diagnosis, stage, biomarkers, prior treatment, organ function and other clinical factors.
Evidence
Evidence should be assessed by study design, population, endpoints, regulatory status and applicability to the individual case.
Limitations
Potential benefits, uncertainties, adverse effects and alternatives require professional medical assessment.
Medical notice: This content is for information and evidence orientation only and does not replace medical diagnosis or treatment decisions.